Depo-subq Provera Injection, Suspension
Product Images NDC 0009-4709

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Depo-subq Provera (NDC 0009-4709). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Depo Subq Provera 01)

Illustration showing a prefilled syringe and a needle with safety shield for Depo-SubQ Provera (medroxyprogesterone acetate) 104 mg/.65 mL injection suspension. The needle is covered by a plastic cap and safety shield, with a needle length of 3/8 inch indicated.*

FDA Label Image

Figure B (Depo Subq Provera 02)

Illustration showing recommended injection sites on the human body for subcutaneous administration. The diagram highlights the lower abdomen, upper buttocks, and anterior thighs as injection areas.*

FDA Label Image

Figure C (Depo Subq Provera 03)

An instructional illustration showing two hands holding syringes, demonstrating a tilting motion with arrows indicating the movement. The image likely depicts a step in preparing an injection, specifically for Depo-SubQ Provera (medroxyprogesterone acetate) suspension for subcutaneous injection.*

FDA Label Image

Figure D (Depo Subq Provera 04)

An instructional illustration depicting hands preparing a syringe, showing one hand holding the syringe barrel and another hand twisting the plunger. The image is likely related to the administration or preparation of an injectable suspension, such as Depo-SubQ Provera (medroxyprogesterone acetate).*

FDA Label Image

Figure E (Depo Subq Provera 05)

An instructional illustration showing hands preparing a syringe with a small vial or container attached to the top. The hands are depicted pulling a small cap or protective covering off the top of the vial, with an arrow pointing downward indicating the direction of removal. This diagram is likely demonstrating a step in the preparation of an injection suspension.*

FDA Label Image

Figure F (Depo Subq Provera 06)

An instructional illustration showing a person using their hands to activate a prefilled injection device. One hand holds the device horizontally, while the other hand pushes a component downward, indicated by an arrow, to prepare the injection for use.*

FDA Label Image

Figure G (Depo Subq Provera 07)

An instructional illustration showing two hands demonstrating the removal of a clear plastic cover from a syringe or injection device, with an arrow indicating the direction of removal. The image likely relates to subcutaneous injection preparation for Depo-SubQ Provera.*

FDA Label Image

Figure H (Depo Subq Provera 08)

An instructional illustration showing a pair of hands preparing a syringe. The image depicts one hand holding a vial while the other pulls the plunger of the syringe upward, indicating the step of drawing medication into the syringe for injection.*

FDA Label Image

Figure I (Depo Subq Provera 09)

An instructional illustration showing the correct subcutaneous injection technique. The syringe is held at a 45-degree angle to the skin, which is pinched up by the other hand to create a fold for the injection site.*

FDA Label Image

Figure J (Depo Subq Provera 10)

An instructional line drawing illustrating the subcutaneous injection technique. The image shows a hand pinching the skin to form a fold while inserting a syringe needle at a 45-degree angle into the skin fold, demonstrating proper injection method for subcutaneous administration.*

FDA Label Image

Figure K (Depo Subq Provera 11)

An instructional illustration showing two hands holding a syringe for injection. The first hand is holding the syringe with the needle cap attached, and the second hand demonstrates removing the needle cap from the syringe. This image provides a visual guide related to the preparation of an injection, such as the subcutaneous Depo-SubQ Provera medroxyprogesterone acetate injection.*

FDA Label Image

Figure L (Depo Subq Provera 12)

An instructional illustration showing a hand holding a small rectangular cloth or pad, pressing it against the skin, likely demonstrating cleaning or preparation of the injection site for subcutaneous administration.*

FDA Label Image

Figure M (Depo Subq Provera 13)

A forest plot chart showing odds ratios from multiple studies related to DMPA use and associated risk. The x-axis represents the odds ratio on a logarithmic scale, with ratio values and confidence intervals displayed for each referenced study, indicating risk assessment for DMPA use duration and subject groups.*

FDA Label Image

Figure N (Depo Subq Provera 14)

A bar chart depicting the mean number of days with bleeding and/or spotting over 12 months for Depo-SubQ Provera injection. The vertical axis shows the number of days (mean, 25th, and 75th percentiles), and the horizontal axis represents months 1 through 12, with sample sizes indicated below each month. Error bars show variability in days of bleeding/spotting.*

FDA Label Image

Figure O (Depo Subq Provera 15)

A bar chart illustrating the mean, 25th percentile, and 75th percentile number of days with bleeding and/or spotting per month over six months. The x-axis lists months 1 through 6 with sample sizes, and the y-axis shows the number of days ranging from 0 to 30. Each bar represents the duration of bleeding or spotting with error bars indicating variability.*

FDA Label Image

Chemical Structure (Depo Subq Provera 16)

Chemical structure of medroxyprogesterone acetate, the active ingredient in Depo-SubQ Provera injection suspension.*

FDA Label Image

Figure P (Depo Subq Provera 17)

A line graph showing the serum concentration of medroxyprogesterone acetate (MPA) over time in days. The y-axis measures MPA serum concentration in ng/mL, and the x-axis measures time up to about 150 days. Data points with error bars indicate variability at each time interval, demonstrating a general decline in serum concentration over time following administration.*

FDA Label Image

Figure Q (Depo Subq Provera 18)

Bar chart comparing percentages of dysmenorrhea, dyspareunia, pelvic pain, pelvic tenderness, and induration among subjects in Study 268 and Study 270, receiving Depo-SubQ Provera 104 mg or leuprolide. The chart shows symptom frequency by study group with distinct bar patterns for each treatment group.*

FDA Label Image

Logo (Depo Subq Provera 19)

FDA Label Image

Logo (Depo Subq Provera 20)

FDA Label Image

Principal Display Panel (0.65 mL Syringe Label)

Label for Depo-SubQ Provera 104 mg/0.65 mL injection, a subcutaneous suspension of medroxyprogesterone acetate. The label indicates a single dose syringe and includes storage instructions, manufacturer Pharmacia & Upjohn Co, along with barcode and lot/expiration fields.*

FDA Label Image

Principal Display Panel (0.65 mL Syringe Carton)

Depo-SubQ Provera 104 mg/0.65 mL prefilled syringe injection, suspension label for subcutaneous use. Contains medroxyprogesterone acetate. Packaging includes manufacturer information: Pharmacia & Upjohn Company LLC, a division of Pfizer Inc. Instructions for use and storage conditions (20°C to 25°C) are also visible, along with the NDC 0009-4709 on the box design.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.